Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
“We are looking forward to meeting with some of the world’s leading cancer clinicians and researchers at this year’s AACR meeting, as we continue to build our human tissue precision medicine platform and expand the areas we are exploring to include additional indications such as breast and ovarian cancers,” said
Poster presentations:
Poster Title: Enriching for adenosine antagonist patient responses through deep learning
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: #4150
Date/Time:
Poster Title: AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7
Session Title: Emerging New Anticancer Agents
Abstract Number: #3930
Date/Time:
Poster Title: Deep Learning Supported Analysis of Primary Samples Identifies ALK Pathway as a Novel Sensitivity in Ovarian Cancer
Session Title: New Technologies for Drug Discovery
Abstract Number: #1893
Date/Time:
About
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, preclinical studies and clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its precision medicine platform and AI-driven drug discovery platform. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005536/en/
Investors:
investors@exscientia.ai
Media:
media@exscientia.ai
Source: